ClinicalTrials.gg
Active, not recruitingNCT07447453MOTIVAUpdated Sep 16, 2026

Motivational Support for an Autonomous Exercise Program for Healthy Aging

An interventional study of MOTIVA ecosystem in Frailty at Older Adults, sponsored by Hospital Universitario Getafe. Active, not recruiting at 2 sites in Spain. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Hospital Universitario Getafe · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.

Planned enrollment
24th of 96
190 · median 90
Started
2025
with 15 others
No phase
93 of 132
34 open now
Primary completion
2026-07
later than 25 of 53 live
Registered
110th of 132
by date
Lead sponsor
6 of 132
Hospital Universitario Getafe

Among the 132 studies in Frailty with a site in Spain, this one is the 24th largest by planned enrollment of the 96 interventional ones that give a count, is one of 16 that started in 2025, is one of 93 with no phase, reaches primary completion later than 25 of the 53 other live ones, and was the 110th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 70 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Frailty with a site in Spain, or all of them as a file.
02

Study summary

An effective implementation of an exercise programme such as VIVIFRAIL, in an unsupervised mode, requires a careful consideration of the patient's motivational traits and state, and the adaptation of the interventions to the current stage in the behaviour change process, as critical countermeasures to fight against abandonment and lack of compliance. A computational ecosystem with motivational support, and functional and performance assessment for an autonomous exercise programme will improve the robust and prefrail community-dwelling older adults' independence and their physical and cognitive health, while reducing healthcare utilisation.

03

Conditions studied

  • Frailty at Older Adults

Browse trials for

Keywords

  • Frailty
  • Clinical trial
  • Motivational profile
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 70 years of age or older.
  • Obtain a score of 4 or higher on the SPPB.
  • Be able to ambulate, with or without assistance.

Exclusion criteria

Exclusion Criteria:

  • Be unable to give consent or refuse to do so.
  • Be unable to understand the instructions.
  • Have a diagnosis of a disease or clinical condition that, in the researcher's judgment, contraindicates physical exercise.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
190 participants (estimated)

Study arms

  • No intervention
    Control group

    VIVIFRAIL Application + ecosystem MOTIVA +NONE motivational support.

  • Experimental
    intervention arm

    VIVIFRAIL Application + ecosystem MOTIVA + A personalized exercise monitoring and encouragement plan based on the user's motivational profile.

    Other: MOTIVA ecosystem

Interventions

  • OtherMOTIVA ecosystem

    A personalized exercise plan based on the user's motivational profile and performance, without professional supervision or a caregiver.

06

What researchers measure

Primary outcomes

  1. MOTIVA Ecosystem

    Compare the number of exercises performed (#exercises per session) in each VIVIFRAIL program session to the total number of sessions (adherence) between the control and intervention groups

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. SPPB (The Short Physical Performance Battery)

    Assess the functional status of participants (Score of SPPB scale) 0-4 points: Severe limitation of mobility. 4-6 points: Moderate limitation. 7-9 points: Mild limitation. 10-12 points: Minimal limitation.

    Time frame: From enrollment to the end of treatment at 12 months

  2. global assement

    Assess the physical (SPPB test, EUROQL5d score, Lawton score, fall/ last 6 months), emotional health (Yesavage Questionnaire) of participants, before and after enrollment in the study

    Time frame: From enrollment to the end of treatment at 12 months

  3. Digital assement

    Describe whether or not there has been an improvement in the digital skills of our older adults by: 1- Score of usability \> 80.3: A (Excellent). Users love the system and will recommend it. 68 - 80: B/C (Good/Acceptable). The system is usable, but there is room for improvement. 51 - 67: D (Poor/Acceptable). The system has significant usability problems. \< 50: F (Unacceptable). The system is very difficult to use. 2-Score of UEQ test Between -0.8 and 0.8: Considered neutral (average). Scores \> 0.8: Positive. Scores \> 1.5: Excellent.

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

2 sites
  • Hospital Universitario Getafe
    Getafe, Madrid 28905, Spain
  • Primary Care
    Madrid, Madrid 28041, Spain
08

References and documents

Publications

  • Angulo J, El Assar M, Alvarez-Bustos A, Rodriguez-Manas L. Physical activity and exercise: Strategies to manage frailty. Redox Biol. 2020 Aug;35:101513. doi: 10.1016/j.redox.2020.101513. Epub 2020 Mar 20. PubMed 32234291 ↗

Individual participant data

Plan to share: Undecided — It is necessary to consult it with the entire consortium.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2026, 15 months.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Mar 3, 2026
StartActual
Apr 8, 2025
Primary completionActual
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447453
Lead sponsor
Hospital Universitario Getafe
Collaborators
Universidad Politecnica de Madrid
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Apr 8, 2025
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Olga Laosa Zafra, MD. PhD
principal investigator · Fundación para la Investigación Biomédica - Hospital Universitario de Getafe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion